Lai Mei Pharmaceutical: Injection of Amorlfine drug supplementary application approved.

Lai Mei Pharmaceutical announced that it has recently received the Injection Amikacin Drug Supplementary Application Approval Letter issued by the National Medical Products Administration. The drug is used to treat infections caused by sensitive Gram-negative bacteria: urinary tract, lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, and gynecological infections.